Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10260024 | 1.00 | FFAR1 (0.59) | FFAR1SLC6A4GSK3BCES2CES1 | |
| SCHEMBL436754 | 1.00 | FFAR1 (0.59) | FFAR1SLC6A4GSK3BCES2CES1 | |
| SCHEMBL434118 | 0.88 | FFAR1 (0.59) | FFAR1SLC6A4GSK3BMAPTSMN1; SMN2 | |
| SCHEMBL434119 | 0.88 | FFAR1 (0.59) | FFAR1SLC6A4GSK3BMAPTSMN1; SMN2 | |
| SCHEMBL10267037 | 0.88 | FFAR1 (0.59) | FFAR1SLC6A4GSK3BMAPTSMN1; SMN2 | |
| SCHEMBL22668296 | 0.87 | FFAR1 (0.64) | FFAR1SLC6A4MAPTSMN1; SMN2NPC1 | |
| SCHEMBL10260740 | 0.87 | FFAR1 (0.58) | FFAR1SLC6A4MAPTSMN1; SMN2NPC1 | |
| SCHEMBL15239272 | 0.86 | FFAR1 (0.47) | FFAR1SLC6A4GSK3BMAPTSMN1; SMN2 | |
| SCHEMBL15239273 | 0.86 | FFAR1 (0.47) | FFAR1SLC6A4GSK3BMAPTSMN1; SMN2 | |
| SCHEMBL15239457 | 0.85 | FFAR1 (0.46) | FFAR1MAPTSMN1; SMN2L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013057743-A1 | PROCESS FOR THE PREPARATION OF AN ARYL OXIME AND SALTS THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD (IN) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057743-A1 | PROCESS FOR THE PREPARATION OF AN ARYL OXIME AND SALTS THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD (IN) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | FFAR1 24/4885SLC6A4 986/4885GSK3B 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.